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ABSTRACT 
Title: 
Introduction: Pharmacogenomic studies contribute to genetic information in preventing 
severe side effects of drugs. Genetic polymorphisms in drug metabolizing enzymes such 
as dihydropyrimidine dehydrogenase (DPD) had been associated with variable clinical 
outcomes in many commonly prescribed chemotherapy drugs including 5-Fluorouracil 
and irinotecan. 
Objectives: The review of literature had shed lights to the importance and possible 
impact of genetic polymorphism of DPYD and TPMT in individualization of drug therapy 
for 5-FU and thiopurines. However, there were no data reported for Malaysian. Current 
study thus aimed to explore the role of pharmacogenetics in personalized medicine in our 
own population. 
Materials and methods: Genotyping methods for DPYD and TPMT were developed 
using dHPLC and allele specific PCR respectively. 5-FU levels were measured in 
colorectal cancer patients using developed method. DNA from healthy volunteers and 
patients were screened. 
Results: Genotyping of DPYD had detected one reported mutation DPYD*5, two new 
mutations in exon 14 1823 T>C and 1827 G>A and one intronic reagion of exon 13, 13 
IVS-11G>A with allele frequencies of 14.5%, .9.1%, 9.1% and 0.9% respectively. 
Genotyping for TPMT revealed 7 (7%) to be heterozygous for TPMT variant alleles. The 
predominant allele detected is TPMT*3C and is in concordance with previous studies 
done on Southeast Asian populations. 
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